The France Single-use Bioprocessing Market was valued at $255.7 Million in 2025 and projected to reach to $406.8 Million by 2030, representing a compound annual growth rate of 9.7%. France's single-use bioprocessing market is poised for sustained growth, driven by the country's strategic focus on biopharmaceutical manufacturing and CDMO capabilities.
France's single-use bioprocessing market is valued at USD 255.7 million in 2025, with projections reaching USD 406.8 million by 2030, representing a robust 9.7% CAGR over the forecast period.
France is strengthening its position as a key hub for contract development and manufacturing organization (CDMO) services, driven by increasing demand for flexible, cost-effective biopharmaceutical production solutions.
Significant investment in advanced bioprocessing infrastructure across France is supporting the adoption of single-use technologies, reducing capital expenditure and accelerating time-to-market for biopharmaceutical companies.
France's alignment with EU regulatory frameworks and strong life sciences ecosystem provides a competitive advantage for bioprocessing innovation and manufacturing excellence in the region.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | CONSUMABLES (Product) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 13.3% from 2025 to 2030 |
| Largest Segment | CONSUMABLES (Product) |
| Market Size Base Year (Billions) | ~USD 18.03 (2025) |
| Revenue Forecast (Billions) | ~USD 33.67 (2030) |
| Segments Covered | Product, Type, Scale Range, Scale |
4 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|
France's single-use bioprocessing market was valued at USD 255.7 million in 2025 and is expected to grow to USD 406.8 million by 2030.
France's single-use bioprocessing market is projected to grow at a compound annual growth rate (CAGR) of 9.7% from 2025 to 2030.
France is adopting single-use bioprocessing to reduce manufacturing costs, improve operational flexibility, and meet the growing demand for biopharmaceutical production from both established and emerging biotech companies.
France's pharmaceutical manufacturing sector, contract development and manufacturing organizations (CDMOs), and emerging biotechnology companies are the primary drivers of single-use bioprocessing adoption.
France's single-use bioprocessing market is forecast to reach USD 406.8 million by 2030, representing significant growth from the 2025 baseline of USD 255.7 million.
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information to analyze the global single-use bioprocessing market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the single-use bioprocessing market. The secondary sources used for this study include the World Health Organization (WHO), the National Institutes of Health (NIH), the United States Food and Drug Administration (US FDA), the National Institute for Bioprocessing Research and Training (NIBRT), the Society for Biological Engineering (SBE), Bio-Process Systems Alliance (BPSA), the European Patent Office (EPO), Pharmaceuticals Export Promotion Council of India (Pharmexcil), India Brand Equity Foundation (IBEF), Biotechnology Innovation Organization (BIO), the National Center for Biotechnology Information (NCBI), BioPharm International, EvaluatePharma, ScienceDirect, BioProcess International, Journal of Bioprocessing and Biotechni ques, BioPlan Associates, Eurostat, and Factiva, research journals; corporate filings, such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
After acquiring foundational knowledge about the global single-use bioprocessing market through secondary research, extensive primary research was conducted. Multiple interviews were held with market experts from the demand side, including representatives from pharmaceutical and biotechnology companies, contract manufacturing organizations (CMOs) & contract research organizations (CROs), and academic & research institutes. Additionally, experts from the supply side were interviewed, including C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.
These interviews spanned five major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while the remaining 30% were with demand-side participants. The primary data was collected through various methods, including questionnaires, emails, online surveys, personal interviews, and telephone interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the single-use bioprocessing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
After arriving at the overall market size from the estimation process, the total market was split into several segments and subsegments.

After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Single-use bioprocessing refers to the use of disposable, pre-sterilized equipment and consumables in the production of biopharmaceutical products. Single-use technologies (SUTs) include a range of products, such as bioreactors, mixers, filters, tubing, connectors, and storage bags, all designed for one-time use. Key benefits of single-use bioprocessing include reduced risk of cross-contamination, low capital and operational costs, faster turnaround times, and greater flexibility in manufacturing. These advantages make single-use systems particularly attractive to produce biologics, vaccines, and personalized medicines, where flexibility, speed, and sterility are paramount.
Full forecast, segment splits, and company analysis for all Single-use Bioprocessing Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report